These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38088845)

  • 1. [Modern aspects influencing the management of patients with papillary thyroid cancer].
    Skibitskaya MV; Kuznetsov NS
    Khirurgiia (Mosk); 2023; (12):89-94. PubMed ID: 38088845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic utility of BRAF mutation in papillary thyroid cancer.
    Xing M
    Mol Cell Endocrinol; 2010 May; 321(1):86-93. PubMed ID: 19883729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
    Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
    Xu B; Serrette R; Tuttle RM; Alzumaili B; Ganly I; Katabi N; Tallini G; Ghossein R
    Thyroid; 2019 Dec; 29(12):1792-1803. PubMed ID: 31452453
    [No Abstract]   [Full Text] [Related]  

  • 6. The synergic effect of BRAF
    Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
    Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cystic cervical lymph node swelling - Thyroglobin-FNA allows to diagnose metastasizing papillary thyroid carcinoma].
    Smaxwil C; Esianu E; Altmeier J; Zielke A
    Laryngorhinootologie; 2022 Aug; 101(8):669-670. PubMed ID: 35915904
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinicopathological features of incidentally detected metastatic thyroid papillary carcinoma in cervical lymph nodes of non-thyroid cancer patients: a retrospective analysis of 31cases.
    Hu C; Zhang H; Chu L; Qiu T; Lu H
    Diagn Pathol; 2023 Jul; 18(1):82. PubMed ID: 37454141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
    Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
    Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: A New Entity: Multiple Differentiated Variant of Papillary Thyroid Carcinoma With Advanced Clinical Behavior.
    Yang J; Gong R; Ma Y; Gao J; Li Z; Zhu J; Gong Y
    Front Endocrinol (Lausanne); 2021; 12():654638. PubMed ID: 33897621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
    Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension.
    Ricarte-Filho J; Ganly I; Rivera M; Katabi N; Fu W; Shaha A; Tuttle RM; Fagin JA; Ghossein R
    Thyroid; 2012 Jun; 22(6):575-84. PubMed ID: 22471242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.
    Kim SK; Lee JH; Woo JW; Park I; Choe JH; Kim JH; Kim JS
    Head Neck; 2016 Apr; 38 Suppl 1():E1203-9. PubMed ID: 26268700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
    Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
    [No Abstract]   [Full Text] [Related]  

  • 16. Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma.
    Shi CL; Sun Y; Ding C; Lv YC; Qin HD
    Genet Mol Res; 2015 Jul; 14(3):7377-85. PubMed ID: 26214416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship and clinical significance between mutated BRAF with prophylactic central-neck nodal dissection in papillary thyroid carcinoma].
    Zhang YJ; Liu BG; Zhao ZY; Sheng JD; Feng DD
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):502-6. PubMed ID: 27318915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.
    Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Strupas K
    Langenbecks Arch Surg; 2017 Mar; 402(2):227-234. PubMed ID: 28160058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm.
    Kim SK; Park I; Woo JW; Lee JH; Choe JH; Kim JH; Kim JS
    Thyroid; 2017 Feb; 27(2):207-214. PubMed ID: 27750022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.